Tirzepatide is currently (March 21, 2023) only available for the treatment of Type-2 diabetes and not (yet) weight loss
Follow institutional laboratory protocols for storage, preparation, and disposal
There is no research to support this claim, and it hasnt been reported in clinical trials
Of note, only four of the articles specifically indicated that the initial 120 weeks of GLP-1 RA treatment was associated with an increase in retained gastric contents, with the highest increase within the first 12 weeks (Ushakumari and Sladen 2024
Hair cycle abnormalities cause hair disorders, including alopecia
Los medicamentos GLP-1 pueden causar efectos secundarios gastrointestinales significativos (nuseas, vmitos, diarrea) en 20-40% de los pacientes